The results of alcoholic septal ablation in the treatment of hypertrophic cardiomyopathy

B.M. Todurov, G.I. Kovtun, A.V. Khokhlov, O.V. Pantazi, A.O. Shpachuk, A.Yu. Melnik, A.O. Maksakov, A.S. Batsiun


1. Angelini P. The 1st septal unit in hypertrophic obstructive cardiomyopathy: a newly recognized anatomo-functional entity, identified during recent alcohol septal ablation experience. Tex Heart Inst. J.2007;34 (3):336–346.
2. Argulian E, Sherrid MV, Messerli F.H. Misconceptions and Facts About Hypertrophic Cardiomyopathy. Am J Med. 2016;129 (2):148–152. doi: 10.1016/j.amjmed.2015.07.035.
3. Cooper RM, Binukrishnan SR, Shahzad A, Hasleton J, Sigwart U, Stables RH. Computed tomography angiography planning identifies the target vessel for optimum infarct location and improves clinical outcome in alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Euro Intervention. 2017;12 (18):e2194–e2203. doi: 10.4244/EIJ-D-15-00159.
4. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G. 2014 ESC Guidelines on diagnosis and managet of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35 (39):2733–2779. doi: 10.1093/eurheartj/ehu284.
5. Holmes DR. Jr, Valeti US, Nishimura RA. Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique. Catheter. Cardiovasc Interv. 2005;66 (3):375–389. doi: 10.1002/ccd.20500.
6. Houston BA, Stevens GR. Hypertrophic cardiomyopathy: a review. Clin Med Insights Cardiol. 2015;8(1):53–65. doi: 10.4137/CMC.S15717.
7. Khouzam RN, Naidu SS. Current status and future perspectives on alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Curr Cardiol Rep. 2014;16 (5):478. doi: 10.1007/s11886-014-0478-36.
8. O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35 (30):2010–2020. doi: 10.1093/eurheartj/eht439.
9. Patel P, Dhillon A, Popovic ZB, Smedira NG, Rizzo J, Thamilarasan M, Agler D, Lytle BW, Lever HM, Desai MY. Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy Patients Without Severe Septal Hypertrophy: Implications of Mitral Valve and Papillary Muscle Abnormalities Assessed Using Cardiac Magnetic Resonance and Echocardiography Circ Cardiovasc Imaging. 2015;8 (7):e003132. doi: 10.1161/CIRCIMAGING.115.003132.
10. Rigopoulos AG, Seggewiss H. A decade of percutaneous septal ablation in hypertrophic cardiomyopathy. Circ J. 2011;75 (1):28–37. doi: 10.1253/circj.cj-10-0962.
11. Sawaya FJ, Louvard Y, Spaziano M, Morice M-C, Hage F, El-Khoury C, Roy A, Garot P, Hovasse T, H Benamer, Unterseeh T, Chevalier B, Champagne S, Piechaud J-F, Blanchard D, Cormier B, Lefèvre T. Shortand long-term outcomes of alcohol septal ablation with the trans-radial versus the trans-femoral approach: A singlecenter-experience. Int J Cardiol. 2016;220:7–13. doi: 10.1016/j.ijcard.2016.06.127.
12. Schuller JL, Zipse MM, Krantz MJ, Blaker B, Salcedo E, Groves BM, Messenger JC, Beaty B, Sauer WH. Incidence and predictors of late complete heart block after alcohol septal ablation treatment of hypertrophic obstructive cardiomyopathy. J Interv Cardiol. 2015;28(1):90–97. doi: 10.1111/joic.12178.
13. Veselka J, Krejčí J, Tomašov P, Zemánek D. Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population. Eur Heart J. 2014;35 (30):2040–2045. doi: 10.1093/eurheartj/eht495. 

[PDF] [Contents]